JG26 is an ADAM17 inhibitor. JG26 also inhibits AngII-induced EGFR transactivation and ERK activation in cultured vascular smooth muscle cells (VSMCs). References: Pharmacological Inhibition of ADAM17 by a Human-Cross Reactive Antibody and Selective Inhibitor JG26 Prevents Vascular Fibrosis Induced by Angiotensin II in vivo and in vitro. Tatsuo Kawai, Steven J Forrester, Kunie Eguchi, Victor Rizzo, Satoru Eguchi, Hang Fai Kwok, Gillian Murphy and Armando Rossello. Arteriosclerosis, Thrombosis, and Vascular Biology. 2016;36:A557, originally published February 9, 2017

纯度：≥98%

CAS：1464910-32-4